Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496699 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL497016 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL151083 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL496726 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL437985 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL908021 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL304724 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL303808 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL22608765 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 | |
| SCHEMBL150843 | 1.00 | FAAH (0.56) | FAAHEPHX2CA2APPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234135-A1 | Gossypol co-crystals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2005-10-20 | — | — | US | claimed |
| US-20120302629-A1 | BIOMARKERS FOR GOSSYPOL CHEMOTHERAPY AND METHODS OF TREATING DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2011017145-A2 | BIOMARKERS FOR GOSSYPOL CHEMOTHERAPY AND METHODS OF TREATING DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100189683-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | ASCENTA THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010056932-A1 | PULSATILE DOSING OF GOSSYPOL FOR TREATMENT OF DISEASE | ASCENTA THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2152076-A1 | PULSATILE DOSING OF GOSSYPOL FOR TREATMENT OF DISEASE | Ascenta Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090082445-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2009-03-26 | — | — | US | disclosed |
| EP-1732529-A4 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | UNIV MICHIGAN (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008150506-A1 | PULSATILE DOSING OF GOSSYPOL FOR TREATMENT OF DISEASE | ASCENTA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7432300-B2 | Gossypol co-crystals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-07 | — | — | US | disclosed |
| US-7342046-B2 | Gossypol co-crystals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070293585-A1 | Gossypol co-crytals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-12-20 | — | — | US | disclosed |
| EP-1732529-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050234135-A1 | Gossypol co-crystals and the use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2005-10-20 | — | — | US | disclosed |
| WO-2005094804-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293585-A1 | Gossypol co-crytals and the use thereof | CRYAB, CRYAA, BAX | FAAH 1003/4885EPHX2 1763/4885CA2 50/4885 |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | BCL2, BAX, PHLPP2 | FAAH 2824/4885EPHX2 3745/4885CA2 2200/4885 |
| US-20050234135-A1 | Gossypol co-crystals and the use thereof | BAX, BCL2, CASP8 | FAAH 1100/4885EPHX2 2429/4885CA2 94/4885 |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | BCL2, BAX, BAD | FAAH 2710/4885EPHX2 3877/4885CA2 2234/4885 |
| US-20090082445-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | BAX, BCL2, CASP8 | FAAH 1100/4885EPHX2 2429/4885CA2 94/4885 |
| US-20100189683-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | BCL2, BAX, PHLPP2 | FAAH 2824/4885EPHX2 3745/4885CA2 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.